Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Molnupiravir (Valenta) vs Lagevrio in Healthy Volunteers
NCT05412173Phase 1Completed
- Sponsor
- Valenta Pharm
- Start
- Apr 2022
- Primary completion
- May 2022
- Modality
- RNA-Targeting Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of molnupiravir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Valenta Pharm. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Plasma Concentration and 9 more. Started Apr 2022; status: completed.
02
Drugs
molnupiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05412173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05412173.